Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages (opens in a new tab)

medicalxpress.com · 2026-09-26

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One key claim is not backed by the study. 3 other points were not covered by the paper.

  • 1 supported
  • 1 not supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim isn't supported by the study. One of five checks out. Three claims the study doesn't address.

  • 1 supported
  • 1 not supported
  • 3 not covered
Open claim evidence
3

The source study

1716-P: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2

Diabetes · 2026
Open source record (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not supportedSignificant reductions in waist circumference of up to 12.5 cm were observed across subgroups receiving orforglipron, and up to 83% of women receiving orforglipron lost at least 5% of their body weight versus 30% receiving placebo.View evidenceHide evidence

As statedup to 12.5 cm; up to 83% vs 30%

Why this verdict

The qualitative direction is supported: the profile reports significant waist-circumference reductions and higher proportions achieving ≥5% weight loss with orforglipron. However, the stated magnitudes do not match the paper profile. The profile reports waist-circumference reduction up to 11 cm, not 12.5 cm, and up to 83% achieving ≥5% weight loss with orforglipron versus 23% with placebo, not 30%. Because the numerical values are material to the claim and conflict with the supplied profile, the claim as stated is unsupported.

1

Study evidence

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”
2

Study evidence

Proportion achieving ≥5% body-weight reduction at 72 weeks was higher with OFG than placebo; abstract reports up to 83% with OFG vs 23% with placebo.Up to 83% (OFG) vs 23% (placebo) for ≥5% weight loss (as reported in abstract)

“...the proportion achieving BW reduction thresholds (≥5%, ≥10%, ≥15%, ≥20%) vs placebo were assessed at 72 weeks using the efficacy estimand.”
Claim 2 of 5Not coveredNew analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) show that orforglipron was associated with similar weight loss among women before, during and after menopause.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that this was a post-hoc analysis of ATTAIN-1/ATTAIN-2 female participants stratified by pre-, peri-, and post-menopause and that orforglipron produced significant body-weight reductions across menopausal-stage subgroups. However, the headline claim that weight loss was specifically “similar” before, during, and after menopause requires subgroup-specific estimates or formal comparisons that are not provided in the abstract profile. The headline therefore outruns what can be verified at this evidence depth.

1

Study evidence

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”
Claim 3 of 5Not coveredThe study is by Dr. Hunter Thomas Hoffman of Eli Lilly and Company in Indianapolis, the manufacturer of orforglipron, and colleagues.View evidenceHide evidence

Why this verdict

The paper profile notes industry relationships among authors, but it does not provide the full author list, identify Dr. Hunter Thomas Hoffman, or state that Eli Lilly is the manufacturer of orforglipron. This authorship/manufacturer claim cannot be fully verified from the supplied abstract-level profile.

1

Study evidence

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”
Claim 4 of 5Not coveredWomen given orforglipron had significant and similar body weight reductions of up to 14% across all three menopausal stages in both ATTAIN-1 and ATTAIN-2.View evidenceHide evidence

As statedup to 14%

Why this verdict

The abstract profile supports significant body-weight reductions with orforglipron versus placebo, reported as up to 14% at 72 weeks, across menopausal-stage subgroups. But it does not provide subgroup-specific estimates, confidence intervals, or trial-specific results needed to verify that reductions were “similar” across all three menopausal stages or separately present in both ATTAIN-1 and ATTAIN-2 rather than reported in a pooled/harmonized analysis.

1

Study evidence

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”
Claim 5 of 5SupportedOrforglipron was associated with significant body weight reductions in the ATTAIN-1 and ATTAIN-2 studies, and this additional analysis evaluated its effect on body weight in women by menopausal stage.View evidenceHide evidence

Why this verdict

The profile supports that orforglipron had previously demonstrated body-weight reductions in ATTAIN-1 and ATTAIN-2 and that the supplied analysis evaluated orforglipron’s effect on body weight in women by menopausal stage. The story frames the finding associationally, which is compatible with the post-hoc subgroup analysis described in the profile.

1

Study evidence

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The analysis was explicitly post-hoc and subgroup-based, so menopausal-stage findings are exploratory rather than a prespecified primary comparison.

    The story presentation describes the work as new/additional analyses and notes menopausal subgroups, but its listed caveats do not acknowledge the explicit post-hoc nature or the exploratory interpretation of subgroup findings.

    From post-hoc subgroup analysis of randomized trials; post hoc menopausal-stage subgroup responder analysis

  • Waist-circumference reduction magnitude in the profile is up to 11 cm, not 12.5 cm.

    The story states a larger waist-circumference reduction of up to 12.5 cm, which is not reflected in the supplied paper profile.

    From post-hoc subgroup analysis of randomized trials

  • The ≥5% weight-loss responder result in the profile is up to 83% with orforglipron versus 23% with placebo.

    The story correctly reports the 83% orforglipron value but states 30% for placebo, whereas the profile reports 23%.

    From post hoc menopausal-stage subgroup responder analysis

  • The abstract profile lacks subgroup-specific sample sizes, confidence intervals, detailed statistical model specifications, and full numerical breakdowns by menopausal stage.

    The story caveats mention that the work is conference-level rather than a full paper, but they do not mention these specific limitations, which affect interpretation of claims about similarity across menopausal stages.

    From post-hoc subgroup analysis of randomized trials; post hoc menopausal-stage subgroup responder analysis

  • More orforglipron-treated participants moved to lower waist-to-height-ratio categories than placebo, but the abstract does not quantify the magnitude or category definitions.

    The story focuses on body weight, waist circumference, and ≥5% weight-loss response and does not mention the waist-to-height-ratio category-shift outcome or its abstract-level reporting limitations.

    From post-hoc subgroup analysis of randomized trials; post hoc menopausal-stage subgroup responder analysis

3 things the story did carry across
  • The evidence comes from ATTAIN-1 and ATTAIN-2 randomized placebo-controlled trial data in female participants with overweight/obesity, assessed at 72 weeks by menopausal status.
  • Body-weight reductions with orforglipron were reported as statistically significant versus placebo across menopausal-stage subgroups, with up to 14% reduction at 72 weeks.
  • The profile reports industry relationships among authors.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEvaluate whether orforglipron vs placebo reduces body weight and waist-related outcomes in women, stratified by menopausal stage, using post hoc subgroup analyses of ATTAIN-1 and ATTAIN-2 at 72 weeks (efficacy estimand).post-hoc subgroup analysis of randomized trialsExpand

In plain English

Post-hoc subgroup analysis of ATTAIN-1 and ATTAIN-2 randomized trials examined orforglipron (OFG) versus placebo in women with overweight/obesity stratified by menopausal stage (pre-, peri-, post-) using a 72-week efficacy estimand. The abstract reports significant reductions in body weight (up to 14%) and waist circumference (up to 11 cm) with OFG versus placebo (p<0.001), higher proportions achieving prespecified weight-loss thresholds (e.g., up to 83% achieving ≥5% vs 23% with placebo), and greater movement to lower waist-to-height ratio categories with OFG.

Key findings

  • Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction
  • Orforglipron was associated with reductions in waist circumference versus placebo, reported as up to 11 cm decrease at 72 weeks (p<0.001).Up to 11 cm decrease
“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”
What this piece can’t prove
  • Analysis is explicitly described as post-hoc; subgroup findings may be exploratory and not prespecified.
  • Abstract does not report subgroup-specific sample sizes, confidence intervals, or detailed statistical model specifications.

2 further details could not be confirmed from the summary.

2secondary dataAssess categorical responder outcomes (proportions achieving ≥5%, ≥10%, ≥15%, ≥20% weight loss) and shifts in waist-to-height ratio categories by menopausal stage for orforglipron vs placebo.post hoc menopausal-stage subgroup responder analysisExpand

In plain English

Post-hoc menopausal-stage subgroup responder analysis of female participants from the ATTAIN-1 and ATTAIN-2 trials assessing categorical weight-loss responder rates (≥5%, ≥10%, ≥15%, ≥20%) and shifts in waist-to-height ratio (WtHR) categories at 72 weeks using the efficacy estimand. The abstract reports substantially higher proportions achieving responder thresholds with orforglipron (OFG) versus placebo (PBO), including up to 83% achieving ≥5% weight loss with OFG versus 23% with PBO, and more participants on OFG shifting to lower WtHR categories. Analyses are post hoc and the abstract does not provide subgroup-specific counts, full numerical breakdowns by menopausal stage, or detailed statistical methods for responder and shift analyses.

Key findings

  • Proportion achieving ≥5% body-weight reduction at 72 weeks was higher with OFG than placebo; abstract reports up to 83% with OFG vs 23% with placebo.Up to 83% (OFG) vs 23% (placebo) for ≥5% weight loss (as reported in abstract)
  • Significantly higher proportions achieved prespecified categorical weight-loss thresholds (≥5%, ≥10%, ≥15%, ≥20%) with OFG versus placebo (reported p<0.001).p<0.001 (reported for comparisons across thresholds)
“...the proportion achieving BW reduction thresholds (≥5%, ≥10%, ≥15%, ≥20%) vs placebo were assessed at 72 weeks using the efficacy estimand.”
What this piece can’t prove
  • Post-hoc subgroup analysis: findings reported by menopausal stage are secondary and exploratory in nature.
  • Abstract-only reporting: no subgroup sample sizes, confidence intervals, or detailed numerical results for each menopausal stage or each responder threshold are provided.
  • Statistical details missing in abstract: methods for multiplicity control, specific statistical tests, covariate adjustment, and handling of missing data are not described.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

1716-P: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2

Diabetes · 2026

Source record (opens in a new tab)

Why this one

Reasonably sure

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Selected

1716-P: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2

Diabetes · 2026 · Crossref

Source (opens in a new tab)
Candidate

Orforglipron is Associated With Body Weight Reductions Across All Body Mass Index Categories by Sex in Adults With Obesity or Overweight, Without Type 2 Diabetes: ATTAIN-1 Trial Post hoc Analysis

Endocrine Practice · 2026 · Crossref

Source (opens in a new tab)
Candidate

Decision letter for "Predicting the long-term risk of type 2 diabetes and cardiovascular disease with orforglipron in people with overweight or obesity: a post-hoc analysis of the ATTAIN-1 trial"

2026 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.